SlideShare una empresa de Scribd logo
1 de 11
Descargar para leer sin conexión
Market
Scenario
Why How Outcome
By
Akshay Miraje
Prateek Kulshreshtha
Sandeep Kumar
Maulik Shengal
• India represents U.S. $6 billion of the $550 billion global
pharmaceutical industry with its share increasing at 10 % a
year.
• Indian sector represents 8% of the global industry total by
volume, putting it in 4th place worldwide, it accounts for 13%
by value, and its drug exports have been growing 30 %
annually.
• The “organized” sector of India's pharmaceutical industry
consists of 250 to 300 companies, which account for 70 % of
products on the market, with the top 10 firms representing 30
percent.
Market Scenario Why How Outcome
Ranbaxy Daiichi-Sankyo
Largest in the India
8th in largest in the global
general pharmaceuticals
 Serving in over 125 Countries
 Ground operations in 49
countries & Manufacturing in 11
countries.
Strong R&D Base.
2nd largest in Japan
22nd Largest in the world
 Operations in 50
countries.
Producer of high quality
drugs
 Daiichi-Sankyo acquired 34.8% stake in Ranbaxy on 11th
June, 2008
 Picked up another 9.12% through preferential allotment
 It was an all cash transaction.
 Size of the deal: US$ 4.9 Billion
 As per the deal, total value of Ranbaxy was US $ 8.5 Billion.
Market
Scenario How Why Outcome
Market
Scenario How Why Outcome
• Strengthen the position of the company.
• Acquisition will provide low cost manufacturing.
• Market access to over 60 countries
• considerable cost savings in their diversification
initiatives
Daiichi-Sankyo - Benefits
• Company will become one of the top 5 in generic
business.
• Access to Daiichi’s advanced R & D facilities.
• Access to Japanese drug market
• Infusion of an additional $ 1 billion into the company.
• Surplus cash of Rs.3,000 crores flows in.
• The market capitalization goes to $8billion & the net
worth goes up.
Ranbaxy - Benefits
Market
Scenario
How Why Outcome
• Ranbaxy has thrived on selling off-patent drugs in the U.S.
Much more expensive proposition because of litigation
• Growing competition in generics at home and abroad
• Though Ranbaxy did well this year it missed its 2007 target
of becoming a $2-billion company
• The R&D pipeline was not delivering enough products, the
generic market was not generating adequate returns
• Ranbaxy had three choices , It could have spent lots of
money in acquiring a big generic company to grow
inorganically, merge with a global player, or sell-out.
Market
Scenario
How Why Outcome
• The sell-out option was the most profitable, both for the
promoters as well as shareholder
• Daiichi is a leading, research-based pharmaceutical
company
• This deal would enable Ranbaxy to explore their shared
capabilities drug development
• The investing company shall then be amongst the largest
generic manufacturers globally in terms of market share.
• Part of the problem, is that generic drug companies in
Japan are small and doctors do not trust them, by
effectively rebranding Ranbaxy generics under the well-
Market
Scenario
How Why Outcome
• A complementary business combination that provides
sustainable growth that spans the full spectrum of
pharmaceutical business
• An expanded global reach that enables leading market
positions in both mature and emerging markets
• Strong growth potential by effectively managing
opportunities
• Competitiveness by optimizing usage of R&D and
manufacturing facilities of both companies
• It will give Ranbaxy access to Daiichi 's expertise in
research while Daiichi will benefit from low-cost
Market
Scenario
How Why Outcome
• Big threat to the survival of the domestic generic industry
• May just dampen the motivation of other Indian aspirants
who want to emulate Ranbaxy's success in global Pharma
• The acquisition will help Daiichi Sankyo to jump from
number 22 in the global pharmaceutical sector to number
15
• Ranbaxy will gain easier access to the much-coveted
Japanese market by operating from within the Daiichi
Sankyo fold
• The share price of Ranbaxy rose sharply
Market
Scenario
How Why Outcome
• http://www.moneycontrol.com/news/business/daiichi-
acquires-525ranbaxy_362194.html
• http://www.frost.com/prod/servlet/market-insight-
top.pag?docid=88873859
• http://www.investopedia.com/university/mergers/mergers
2.asp#axzz1Xwzuwrtw
• http://www.worldpharmanews.com/corporate/1782-
daiichi-sankyo-a-ranbaxy-announce-a-new-social-
contribution-initiative
Ranbaxy  daiichi

Más contenido relacionado

La actualidad más candente

Sun Pharma - Ranbaxy Merger Presentation
Sun Pharma - Ranbaxy Merger PresentationSun Pharma - Ranbaxy Merger Presentation
Sun Pharma - Ranbaxy Merger PresentationDeepak Shenoy
 
Case of Daiichi Sankyo takeover of Ranbaxy
Case of Daiichi Sankyo takeover of RanbaxyCase of Daiichi Sankyo takeover of Ranbaxy
Case of Daiichi Sankyo takeover of RanbaxyAdityakapoors
 
SWOT Analysis of Sunpharma
SWOT Analysis of SunpharmaSWOT Analysis of Sunpharma
SWOT Analysis of SunpharmaPratik Rahate
 
Xerox npp bpr case (1)
Xerox npp bpr case (1)Xerox npp bpr case (1)
Xerox npp bpr case (1)Abhijeet Dash
 
Marketing Strategy of Sun Pharmaceuticals
Marketing Strategy of Sun PharmaceuticalsMarketing Strategy of Sun Pharmaceuticals
Marketing Strategy of Sun PharmaceuticalsAman Dube
 
Eli lilly ranbaxy case group 4
Eli lilly ranbaxy case group 4Eli lilly ranbaxy case group 4
Eli lilly ranbaxy case group 4Ashish Thakur
 
Tetra threat framework for big bazaar
Tetra threat framework for big bazaarTetra threat framework for big bazaar
Tetra threat framework for big bazaarmj5082
 
Strategic Analysis - Sanofi Aventis
Strategic Analysis - Sanofi AventisStrategic Analysis - Sanofi Aventis
Strategic Analysis - Sanofi AventisBruno Rakotozafy
 
Sun pharma Presentation
Sun pharma PresentationSun pharma Presentation
Sun pharma Presentationshivsharanjak
 
Sun pharma- A complete company review, analysis of crisis and realistic recom...
Sun pharma- A complete company review, analysis of crisis and realistic recom...Sun pharma- A complete company review, analysis of crisis and realistic recom...
Sun pharma- A complete company review, analysis of crisis and realistic recom...TilikaChawda
 

La actualidad más candente (20)

Sun Pharma
Sun Pharma Sun Pharma
Sun Pharma
 
Sunpharma present13
Sunpharma present13Sunpharma present13
Sunpharma present13
 
Sun Pharma - Ranbaxy Merger Presentation
Sun Pharma - Ranbaxy Merger PresentationSun Pharma - Ranbaxy Merger Presentation
Sun Pharma - Ranbaxy Merger Presentation
 
Case of Daiichi Sankyo takeover of Ranbaxy
Case of Daiichi Sankyo takeover of RanbaxyCase of Daiichi Sankyo takeover of Ranbaxy
Case of Daiichi Sankyo takeover of Ranbaxy
 
SWOT Analysis of Sunpharma
SWOT Analysis of SunpharmaSWOT Analysis of Sunpharma
SWOT Analysis of Sunpharma
 
Sun pharma ppt final
Sun pharma ppt finalSun pharma ppt final
Sun pharma ppt final
 
Xerox npp bpr case (1)
Xerox npp bpr case (1)Xerox npp bpr case (1)
Xerox npp bpr case (1)
 
Sun pharma ppt
Sun pharma pptSun pharma ppt
Sun pharma ppt
 
Sun pharma
Sun pharmaSun pharma
Sun pharma
 
Marketing Strategy of Sun Pharmaceuticals
Marketing Strategy of Sun PharmaceuticalsMarketing Strategy of Sun Pharmaceuticals
Marketing Strategy of Sun Pharmaceuticals
 
Eli lilly ranbaxy case group 4
Eli lilly ranbaxy case group 4Eli lilly ranbaxy case group 4
Eli lilly ranbaxy case group 4
 
Tetra threat framework for big bazaar
Tetra threat framework for big bazaarTetra threat framework for big bazaar
Tetra threat framework for big bazaar
 
Dr reddy's
Dr reddy'sDr reddy's
Dr reddy's
 
Dr.reddy
Dr.reddyDr.reddy
Dr.reddy
 
Sun pharma
Sun pharmaSun pharma
Sun pharma
 
Cipla final
Cipla finalCipla final
Cipla final
 
Strategic Analysis - Sanofi Aventis
Strategic Analysis - Sanofi AventisStrategic Analysis - Sanofi Aventis
Strategic Analysis - Sanofi Aventis
 
swot of sun pharma
swot of sun pharmaswot of sun pharma
swot of sun pharma
 
Sun pharma Presentation
Sun pharma PresentationSun pharma Presentation
Sun pharma Presentation
 
Sun pharma- A complete company review, analysis of crisis and realistic recom...
Sun pharma- A complete company review, analysis of crisis and realistic recom...Sun pharma- A complete company review, analysis of crisis and realistic recom...
Sun pharma- A complete company review, analysis of crisis and realistic recom...
 

Similar a Ranbaxy daiichi

Cipla final-150812055505-lva1-app6891
Cipla final-150812055505-lva1-app6891Cipla final-150812055505-lva1-app6891
Cipla final-150812055505-lva1-app6891Nakul Gupta
 
Indian pharmaceutical industry
Indian pharmaceutical industry Indian pharmaceutical industry
Indian pharmaceutical industry Kushal Shah
 
Top generic pharma companies in india ppt
Top generic pharma companies in india pptTop generic pharma companies in india ppt
Top generic pharma companies in india pptAditiMehra14
 
REVIEWS1_12013,12017,12026,12030,12043,12052,12055
REVIEWS1_12013,12017,12026,12030,12043,12052,12055REVIEWS1_12013,12017,12026,12030,12043,12052,12055
REVIEWS1_12013,12017,12026,12030,12043,12052,12055Sandeep David Rao
 
Pharmaceutical industry in india
Pharmaceutical industry in indiaPharmaceutical industry in india
Pharmaceutical industry in indiaSahil Khanna
 
Ranbaxycompanyprofile
Ranbaxycompanyprofile Ranbaxycompanyprofile
Ranbaxycompanyprofile bhawna allagh
 
Sun pharma ranbaxy acquition
Sun pharma ranbaxy acquitionSun pharma ranbaxy acquition
Sun pharma ranbaxy acquitionSai Mahesh
 
Analysis of Pharmaceutical Sector in India
Analysis of Pharmaceutical Sector in IndiaAnalysis of Pharmaceutical Sector in India
Analysis of Pharmaceutical Sector in IndiaAkshay Krishnapurkar
 
Implications for indian_pharmaceuticals
Implications for indian_pharmaceuticalsImplications for indian_pharmaceuticals
Implications for indian_pharmaceuticalsAkshay Bawa
 
Mergers & acquisitions pharma industry
Mergers & acquisitions pharma industryMergers & acquisitions pharma industry
Mergers & acquisitions pharma industryLal Sivaraj
 
Overview of the Pharma industry
Overview of the Pharma industryOverview of the Pharma industry
Overview of the Pharma industrykeyursavalia
 
Rm report ppt1234
Rm report ppt1234Rm report ppt1234
Rm report ppt1234Ram Kashyap
 
Sun pharma profit down but tide may be turning
Sun pharma profit down but tide may be turningSun pharma profit down but tide may be turning
Sun pharma profit down but tide may be turningmadhavlankapati
 
A review of marketing
A review of marketingA review of marketing
A review of marketingNilesh Shah
 

Similar a Ranbaxy daiichi (20)

24444632 ranbaxy-ppt
24444632 ranbaxy-ppt24444632 ranbaxy-ppt
24444632 ranbaxy-ppt
 
Cipla final-150812055505-lva1-app6891
Cipla final-150812055505-lva1-app6891Cipla final-150812055505-lva1-app6891
Cipla final-150812055505-lva1-app6891
 
Indian pharmaceutical industry
Indian pharmaceutical industry Indian pharmaceutical industry
Indian pharmaceutical industry
 
Top generic pharma companies in india ppt
Top generic pharma companies in india pptTop generic pharma companies in india ppt
Top generic pharma companies in india ppt
 
REVIEWS1_12013,12017,12026,12030,12043,12052,12055
REVIEWS1_12013,12017,12026,12030,12043,12052,12055REVIEWS1_12013,12017,12026,12030,12043,12052,12055
REVIEWS1_12013,12017,12026,12030,12043,12052,12055
 
Pharmaceutical industry in india
Pharmaceutical industry in indiaPharmaceutical industry in india
Pharmaceutical industry in india
 
Drl analysis
Drl analysisDrl analysis
Drl analysis
 
Ranbaxycompanyprofile
Ranbaxycompanyprofile Ranbaxycompanyprofile
Ranbaxycompanyprofile
 
Sun pharma ranbaxy acquition
Sun pharma ranbaxy acquitionSun pharma ranbaxy acquition
Sun pharma ranbaxy acquition
 
Pharmaceutical Marketing
Pharmaceutical MarketingPharmaceutical Marketing
Pharmaceutical Marketing
 
Analysis of Pharmaceutical Sector in India
Analysis of Pharmaceutical Sector in IndiaAnalysis of Pharmaceutical Sector in India
Analysis of Pharmaceutical Sector in India
 
Implications for indian_pharmaceuticals
Implications for indian_pharmaceuticalsImplications for indian_pharmaceuticals
Implications for indian_pharmaceuticals
 
Mergers & acquisitions pharma industry
Mergers & acquisitions pharma industryMergers & acquisitions pharma industry
Mergers & acquisitions pharma industry
 
winter project
winter projectwinter project
winter project
 
Ranbaxy
RanbaxyRanbaxy
Ranbaxy
 
National Policy [Autosaved].pptx
National Policy [Autosaved].pptxNational Policy [Autosaved].pptx
National Policy [Autosaved].pptx
 
Overview of the Pharma industry
Overview of the Pharma industryOverview of the Pharma industry
Overview of the Pharma industry
 
Rm report ppt1234
Rm report ppt1234Rm report ppt1234
Rm report ppt1234
 
Sun pharma profit down but tide may be turning
Sun pharma profit down but tide may be turningSun pharma profit down but tide may be turning
Sun pharma profit down but tide may be turning
 
A review of marketing
A review of marketingA review of marketing
A review of marketing
 

Último

Borderless Access - Global Panel book-unlock 2024
Borderless Access - Global Panel book-unlock 2024Borderless Access - Global Panel book-unlock 2024
Borderless Access - Global Panel book-unlock 2024Borderless Access
 
NewBase 25 March 2024 Energy News issue - 1710 by Khaled Al Awadi_compress...
NewBase  25 March  2024  Energy News issue - 1710 by Khaled Al Awadi_compress...NewBase  25 March  2024  Energy News issue - 1710 by Khaled Al Awadi_compress...
NewBase 25 March 2024 Energy News issue - 1710 by Khaled Al Awadi_compress...Khaled Al Awadi
 
Mihir Menda - Member of Supervisory Board at RMZ
Mihir Menda - Member of Supervisory Board at RMZMihir Menda - Member of Supervisory Board at RMZ
Mihir Menda - Member of Supervisory Board at RMZKanakChauhan5
 
Entrepreneurship & organisations: influences and organizations
Entrepreneurship & organisations: influences and organizationsEntrepreneurship & organisations: influences and organizations
Entrepreneurship & organisations: influences and organizationsP&CO
 
Michael Vidyakin: Introduction to PMO (UA)
Michael Vidyakin: Introduction to PMO (UA)Michael Vidyakin: Introduction to PMO (UA)
Michael Vidyakin: Introduction to PMO (UA)Lviv Startup Club
 
Borderless Access - Global B2B Panel book-unlock 2024
Borderless Access - Global B2B Panel book-unlock 2024Borderless Access - Global B2B Panel book-unlock 2024
Borderless Access - Global B2B Panel book-unlock 2024Borderless Access
 
Tata Kelola Bisnis perushaan yang bergerak
Tata Kelola Bisnis perushaan yang bergerakTata Kelola Bisnis perushaan yang bergerak
Tata Kelola Bisnis perushaan yang bergerakEditores1
 
PDT 89 - $1.4M - Seed - Plantee Innovations.pdf
PDT 89 - $1.4M - Seed - Plantee Innovations.pdfPDT 89 - $1.4M - Seed - Plantee Innovations.pdf
PDT 89 - $1.4M - Seed - Plantee Innovations.pdfHajeJanKamps
 
AMAZON SELLER VIRTUAL ASSISTANT PRODUCT RESEARCH .pdf
AMAZON SELLER VIRTUAL ASSISTANT PRODUCT RESEARCH .pdfAMAZON SELLER VIRTUAL ASSISTANT PRODUCT RESEARCH .pdf
AMAZON SELLER VIRTUAL ASSISTANT PRODUCT RESEARCH .pdfJohnCarloValencia4
 
NASA CoCEI Scaling Strategy - November 2023
NASA CoCEI Scaling Strategy - November 2023NASA CoCEI Scaling Strategy - November 2023
NASA CoCEI Scaling Strategy - November 2023Steve Rader
 
Ethical stalking by Mark Williams. UpliftLive 2024
Ethical stalking by Mark Williams. UpliftLive 2024Ethical stalking by Mark Williams. UpliftLive 2024
Ethical stalking by Mark Williams. UpliftLive 2024Winbusinessin
 
7movierulz.uk
7movierulz.uk7movierulz.uk
7movierulz.ukaroemirsr
 
Slicing Work on Business Agility Meetup Berlin
Slicing Work on Business Agility Meetup BerlinSlicing Work on Business Agility Meetup Berlin
Slicing Work on Business Agility Meetup BerlinAnton Skornyakov
 
Cracking the ‘Business Process Outsourcing’ Code Main.pptx
Cracking the ‘Business Process Outsourcing’ Code Main.pptxCracking the ‘Business Process Outsourcing’ Code Main.pptx
Cracking the ‘Business Process Outsourcing’ Code Main.pptxWorkforce Group
 
Data skills for Agile Teams- Killing story points
Data skills for Agile Teams- Killing story pointsData skills for Agile Teams- Killing story points
Data skills for Agile Teams- Killing story pointsyasinnathani
 
Introduction to The overview of GAAP LO 1-5.pptx
Introduction to The overview of GAAP LO 1-5.pptxIntroduction to The overview of GAAP LO 1-5.pptx
Introduction to The overview of GAAP LO 1-5.pptxJemalSeid25
 
Anyhr.io | Presentation HR&Recruiting agency
Anyhr.io | Presentation HR&Recruiting agencyAnyhr.io | Presentation HR&Recruiting agency
Anyhr.io | Presentation HR&Recruiting agencyHanna Klim
 
IIBA® Melbourne - Navigating Business Analysis - Excellence for Career Growth...
IIBA® Melbourne - Navigating Business Analysis - Excellence for Career Growth...IIBA® Melbourne - Navigating Business Analysis - Excellence for Career Growth...
IIBA® Melbourne - Navigating Business Analysis - Excellence for Career Growth...AustraliaChapterIIBA
 
Harvard Business Review.pptx | Navigating Labor Unrest (March-April 2024)
Harvard Business Review.pptx | Navigating Labor Unrest (March-April 2024)Harvard Business Review.pptx | Navigating Labor Unrest (March-April 2024)
Harvard Business Review.pptx | Navigating Labor Unrest (March-April 2024)tazeenaila12
 
Borderless Access - Global Panel book-unlock 2024
Borderless Access - Global Panel book-unlock 2024Borderless Access - Global Panel book-unlock 2024
Borderless Access - Global Panel book-unlock 2024Borderless Access
 

Último (20)

Borderless Access - Global Panel book-unlock 2024
Borderless Access - Global Panel book-unlock 2024Borderless Access - Global Panel book-unlock 2024
Borderless Access - Global Panel book-unlock 2024
 
NewBase 25 March 2024 Energy News issue - 1710 by Khaled Al Awadi_compress...
NewBase  25 March  2024  Energy News issue - 1710 by Khaled Al Awadi_compress...NewBase  25 March  2024  Energy News issue - 1710 by Khaled Al Awadi_compress...
NewBase 25 March 2024 Energy News issue - 1710 by Khaled Al Awadi_compress...
 
Mihir Menda - Member of Supervisory Board at RMZ
Mihir Menda - Member of Supervisory Board at RMZMihir Menda - Member of Supervisory Board at RMZ
Mihir Menda - Member of Supervisory Board at RMZ
 
Entrepreneurship & organisations: influences and organizations
Entrepreneurship & organisations: influences and organizationsEntrepreneurship & organisations: influences and organizations
Entrepreneurship & organisations: influences and organizations
 
Michael Vidyakin: Introduction to PMO (UA)
Michael Vidyakin: Introduction to PMO (UA)Michael Vidyakin: Introduction to PMO (UA)
Michael Vidyakin: Introduction to PMO (UA)
 
Borderless Access - Global B2B Panel book-unlock 2024
Borderless Access - Global B2B Panel book-unlock 2024Borderless Access - Global B2B Panel book-unlock 2024
Borderless Access - Global B2B Panel book-unlock 2024
 
Tata Kelola Bisnis perushaan yang bergerak
Tata Kelola Bisnis perushaan yang bergerakTata Kelola Bisnis perushaan yang bergerak
Tata Kelola Bisnis perushaan yang bergerak
 
PDT 89 - $1.4M - Seed - Plantee Innovations.pdf
PDT 89 - $1.4M - Seed - Plantee Innovations.pdfPDT 89 - $1.4M - Seed - Plantee Innovations.pdf
PDT 89 - $1.4M - Seed - Plantee Innovations.pdf
 
AMAZON SELLER VIRTUAL ASSISTANT PRODUCT RESEARCH .pdf
AMAZON SELLER VIRTUAL ASSISTANT PRODUCT RESEARCH .pdfAMAZON SELLER VIRTUAL ASSISTANT PRODUCT RESEARCH .pdf
AMAZON SELLER VIRTUAL ASSISTANT PRODUCT RESEARCH .pdf
 
NASA CoCEI Scaling Strategy - November 2023
NASA CoCEI Scaling Strategy - November 2023NASA CoCEI Scaling Strategy - November 2023
NASA CoCEI Scaling Strategy - November 2023
 
Ethical stalking by Mark Williams. UpliftLive 2024
Ethical stalking by Mark Williams. UpliftLive 2024Ethical stalking by Mark Williams. UpliftLive 2024
Ethical stalking by Mark Williams. UpliftLive 2024
 
7movierulz.uk
7movierulz.uk7movierulz.uk
7movierulz.uk
 
Slicing Work on Business Agility Meetup Berlin
Slicing Work on Business Agility Meetup BerlinSlicing Work on Business Agility Meetup Berlin
Slicing Work on Business Agility Meetup Berlin
 
Cracking the ‘Business Process Outsourcing’ Code Main.pptx
Cracking the ‘Business Process Outsourcing’ Code Main.pptxCracking the ‘Business Process Outsourcing’ Code Main.pptx
Cracking the ‘Business Process Outsourcing’ Code Main.pptx
 
Data skills for Agile Teams- Killing story points
Data skills for Agile Teams- Killing story pointsData skills for Agile Teams- Killing story points
Data skills for Agile Teams- Killing story points
 
Introduction to The overview of GAAP LO 1-5.pptx
Introduction to The overview of GAAP LO 1-5.pptxIntroduction to The overview of GAAP LO 1-5.pptx
Introduction to The overview of GAAP LO 1-5.pptx
 
Anyhr.io | Presentation HR&Recruiting agency
Anyhr.io | Presentation HR&Recruiting agencyAnyhr.io | Presentation HR&Recruiting agency
Anyhr.io | Presentation HR&Recruiting agency
 
IIBA® Melbourne - Navigating Business Analysis - Excellence for Career Growth...
IIBA® Melbourne - Navigating Business Analysis - Excellence for Career Growth...IIBA® Melbourne - Navigating Business Analysis - Excellence for Career Growth...
IIBA® Melbourne - Navigating Business Analysis - Excellence for Career Growth...
 
Harvard Business Review.pptx | Navigating Labor Unrest (March-April 2024)
Harvard Business Review.pptx | Navigating Labor Unrest (March-April 2024)Harvard Business Review.pptx | Navigating Labor Unrest (March-April 2024)
Harvard Business Review.pptx | Navigating Labor Unrest (March-April 2024)
 
Borderless Access - Global Panel book-unlock 2024
Borderless Access - Global Panel book-unlock 2024Borderless Access - Global Panel book-unlock 2024
Borderless Access - Global Panel book-unlock 2024
 

Ranbaxy daiichi

  • 1. Market Scenario Why How Outcome By Akshay Miraje Prateek Kulshreshtha Sandeep Kumar Maulik Shengal
  • 2. • India represents U.S. $6 billion of the $550 billion global pharmaceutical industry with its share increasing at 10 % a year. • Indian sector represents 8% of the global industry total by volume, putting it in 4th place worldwide, it accounts for 13% by value, and its drug exports have been growing 30 % annually. • The “organized” sector of India's pharmaceutical industry consists of 250 to 300 companies, which account for 70 % of products on the market, with the top 10 firms representing 30 percent. Market Scenario Why How Outcome Ranbaxy Daiichi-Sankyo Largest in the India 8th in largest in the global general pharmaceuticals  Serving in over 125 Countries  Ground operations in 49 countries & Manufacturing in 11 countries. Strong R&D Base. 2nd largest in Japan 22nd Largest in the world  Operations in 50 countries. Producer of high quality drugs
  • 3.  Daiichi-Sankyo acquired 34.8% stake in Ranbaxy on 11th June, 2008  Picked up another 9.12% through preferential allotment  It was an all cash transaction.  Size of the deal: US$ 4.9 Billion  As per the deal, total value of Ranbaxy was US $ 8.5 Billion. Market Scenario How Why Outcome
  • 5. • Strengthen the position of the company. • Acquisition will provide low cost manufacturing. • Market access to over 60 countries • considerable cost savings in their diversification initiatives Daiichi-Sankyo - Benefits • Company will become one of the top 5 in generic business. • Access to Daiichi’s advanced R & D facilities. • Access to Japanese drug market • Infusion of an additional $ 1 billion into the company. • Surplus cash of Rs.3,000 crores flows in. • The market capitalization goes to $8billion & the net worth goes up. Ranbaxy - Benefits Market Scenario How Why Outcome
  • 6. • Ranbaxy has thrived on selling off-patent drugs in the U.S. Much more expensive proposition because of litigation • Growing competition in generics at home and abroad • Though Ranbaxy did well this year it missed its 2007 target of becoming a $2-billion company • The R&D pipeline was not delivering enough products, the generic market was not generating adequate returns • Ranbaxy had three choices , It could have spent lots of money in acquiring a big generic company to grow inorganically, merge with a global player, or sell-out. Market Scenario How Why Outcome
  • 7. • The sell-out option was the most profitable, both for the promoters as well as shareholder • Daiichi is a leading, research-based pharmaceutical company • This deal would enable Ranbaxy to explore their shared capabilities drug development • The investing company shall then be amongst the largest generic manufacturers globally in terms of market share. • Part of the problem, is that generic drug companies in Japan are small and doctors do not trust them, by effectively rebranding Ranbaxy generics under the well- Market Scenario How Why Outcome
  • 8. • A complementary business combination that provides sustainable growth that spans the full spectrum of pharmaceutical business • An expanded global reach that enables leading market positions in both mature and emerging markets • Strong growth potential by effectively managing opportunities • Competitiveness by optimizing usage of R&D and manufacturing facilities of both companies • It will give Ranbaxy access to Daiichi 's expertise in research while Daiichi will benefit from low-cost Market Scenario How Why Outcome
  • 9. • Big threat to the survival of the domestic generic industry • May just dampen the motivation of other Indian aspirants who want to emulate Ranbaxy's success in global Pharma • The acquisition will help Daiichi Sankyo to jump from number 22 in the global pharmaceutical sector to number 15 • Ranbaxy will gain easier access to the much-coveted Japanese market by operating from within the Daiichi Sankyo fold • The share price of Ranbaxy rose sharply Market Scenario How Why Outcome
  • 10. • http://www.moneycontrol.com/news/business/daiichi- acquires-525ranbaxy_362194.html • http://www.frost.com/prod/servlet/market-insight- top.pag?docid=88873859 • http://www.investopedia.com/university/mergers/mergers 2.asp#axzz1Xwzuwrtw • http://www.worldpharmanews.com/corporate/1782- daiichi-sankyo-a-ranbaxy-announce-a-new-social- contribution-initiative